OmniAb to Report First Quarter 2025 Financial Results on May 8
OmniAb (NASDAQ: OABI) has announced it will release its first quarter 2025 financial results on Thursday, May 8, 2025, after U.S. financial markets close. The company will host a conference call and webcast on the same day at 4:30 p.m. Eastern time (1:30 p.m. Pacific time) to discuss the quarterly results and provide business updates.
Participants can join via phone using U.S. number (800) 549 8228 or International number (289) 819 1520 with Conference ID 96760. A live webcast with slides will also be available.
OmniAb (NASDAQ: OABI) ha annunciato che rilascerà i suoi risultati finanziari del primo trimestre 2025 giovedì 8 maggio 2025, dopo la chiusura dei mercati finanziari statunitensi. L'azienda ospiterà una conferenza telefonica e un webcast lo stesso giorno alle 16:30 ora orientale (13:30 ora del Pacifico) per discutere i risultati trimestrali e fornire aggiornamenti aziendali.
I partecipanti possono unirsi tramite telefono utilizzando il numero statunitense (800) 549 8228 o il numero internazionale (289) 819 1520 con ID conferenza 96760. Sarà inoltre disponibile un webcast dal vivo con diapositive.
OmniAb (NASDAQ: OABI) ha anunciado que publicará sus resultados financieros del primer trimestre de 2025 el jueves 8 de mayo de 2025, después del cierre de los mercados financieros en EE. UU. La empresa llevará a cabo una llamada de conferencia y un webcast el mismo día a las 4:30 p.m. hora del Este (1:30 p.m. hora del Pacífico) para discutir los resultados trimestrales y proporcionar actualizaciones comerciales.
Los participantes pueden unirse por teléfono utilizando el número de EE. UU. (800) 549 8228 o el número internacional (289) 819 1520 con ID de conferencia 96760. También estará disponible un webcast en vivo con diapositivas.
OmniAb (NASDAQ: OABI)는 2025년 1분기 재무 결과를 2025년 5월 8일 목요일, 미국 금융 시장이 마감한 후 발표할 것이라고 발표했습니다. 회사는 같은 날 동부 표준시 기준 오후 4시 30분(태평양 표준시 기준 오후 1시 30분)에 분기 결과를 논의하고 비즈니스 업데이트를 제공하기 위해 컨퍼런스 콜과 웹캐스트를 개최합니다.
참가자는 미국 번호 (800) 549 8228 또는 국제 번호 (289) 819 1520을 사용하여 전화로 참여할 수 있으며, 회의 ID는 96760입니다. 슬라이드와 함께 실시간 웹캐스트도 제공됩니다.
OmniAb (NASDAQ: OABI) a annoncé qu'il publiera ses résultats financiers du premier trimestre 2025 le jeudi 8 mai 2025, après la fermeture des marchés financiers américains. L'entreprise organisera une conférence téléphonique et un webcast le même jour à 16h30 heure de l'Est (13h30 heure du Pacifique) pour discuter des résultats trimestriels et fournir des mises à jour commerciales.
Les participants peuvent rejoindre par téléphone en utilisant le numéro américain (800) 549 8228 ou le numéro international (289) 819 1520 avec l'ID de conférence 96760. Un webcast en direct avec des diapositives sera également disponible.
OmniAb (NASDAQ: OABI) hat angekündigt, dass es seine Finanzergebnisse für das erste Quartal 2025 am Donnerstag, den 8. Mai 2025, nach Schließung der US-Finanzmärkte veröffentlichen wird. Das Unternehmen wird am selben Tag um 16:30 Uhr Eastern Time (13:30 Uhr Pacific Time) eine Telefonkonferenz und einen Webcast abhalten, um die Quartalszahlen zu besprechen und Unternehmensupdates bereitzustellen.
Teilnehmer können sich telefonisch unter der US-Nummer (800) 549 8228 oder der internationalen Nummer (289) 819 1520 mit der Konferenz-ID 96760 einwählen. Ein Live-Webcast mit Folien wird ebenfalls verfügbar sein.
- None.
- None.
Conference Call and Webcast Information
What: |
|
OmniAb conference call to discuss first quarter 2025 financial results and business updates |
|
|
|
|
|
Date: |
|
Thursday, May 8, 2025 |
|
|
|
|
|
Time: |
|
4:30 p.m. Eastern time (1:30 p.m. Pacific time) |
|
|
|
|
|
Phone: |
|
|
|
|
|
International (289) 819 1520 |
|
|
|
Conference ID is 96760 |
|
|
|
|
|
Webcast: |
Live and replay webcast of the call with slides will be available here. | ||
About OmniAb®
OmniAb licenses cutting edge discovery research technology to pharmaceutical and biotech companies and academic institutions to enable the discovery of next-generation therapeutics. Our technology platform creates and screens diverse antibody repertoires and is designed to quickly identify optimal antibodies and other target-binding proteins for our partners’ drug development efforts. At the heart of the OmniAb platform is something we call Biological Intelligence™, which powers the immune systems of our proprietary, engineered transgenic animals to create optimized antibody candidates for human therapeutics. We believe the OmniAb animals comprise the most diverse host systems available in the industry. Our suite of technologies and methods, including computational antigen design and immunization methods, paired with high-throughput single B cell phenotypic screening and mining of next-generation sequencing datasets with custom algorithms, is used to identify fully-human antibodies with exceptional performance and developability characteristics. We provide our partners both integrated end-to-end capabilities and highly customizable offerings, which address critical industry challenges and provide optimized discovery solutions. Our business model aligns scientific and economic interests of our partners through structured agreements that generally include upfront/access fees, service revenue, milestones and royalties on commercial sales.
For more information, please visit www.omniab.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250414209387/en/
OmniAb, Inc.
Neha Singh, Ph.D.
investors@OmniAb.com
X @OmniAbTech
(510) 768-7760
Source: OmniAb, Inc.
FAQ
When will OmniAb (OABI) release its Q1 2025 earnings?
How can investors join OmniAb's (OABI) Q1 2025 earnings call?
What time is OmniAb's (OABI) Q1 2025 earnings call?
Will OmniAb (OABI) provide Q1 2025 business updates during the earnings call?
